Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixmyelocel-T for Alveolar Bone Defects
NCT00755911Phase 2Completed
- Sponsor
- University of Michigan
- Start
- Jun 2008
- Primary completion
- Dec 2011
- Modality
- Mesenchymal Stem Cells, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ixmyelocel-T in Alveolar bone loss (2 arms), sponsored by University of Michigan. Primary endpoint: Bone Regeneration at 12 months. Started Jun 2008; status: completed.
02
Drugs
ixmyelocel-T
03
Conditions
Alveolar bone loss
Beyond the preview
Go deeper on NCT00755911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00755911.